CClinicalTrials.gg
CompletedNCT02441348Updated Jan 8, 2019

Efficacy of Conversation Training Therapy (CTT)

An observational study in Voice Disorders, sponsored by University of Pittsburgh. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2019-01-08.

Sponsored by University of Pittsburgh · Observational

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
67
Ages
18 Years to 60 Years
Sex
All
01

Study summary

Voice therapy is the standard-of-care for many of the nearly 140 million people in the United States who suffer from voice disorders,1 yet patients claim that current therapies are ineffective at meeting their voice needs.2 Published data by our research team indicate that patients think that transfer of target voice techniques to every day voice use (i.e. conversation) is the most difficult aspect of therapy,2 and that training techniques in conversation is the most useful aspect of voice therapy.2 Unfortunately, traditional voice therapy programs spend little, if any, time training voice techniques in conversation.3 This lack of functional specificity in voice therapy may contribute to the estimated 65% attrition rate.4 Even after some form of treatment, patients are still struggling with daily conversational voice use, and voice disorders continue to cause serious disability, stress and depression, which negatively affects social functioning and job performance.5 A new voice therapy program, Conversation Training Therapy (CTT), based on published patient reports on dissatisfaction with traditional therapy, was developed by the Investigators. It was honed with recommendations from expert clinical voice-specialized speech-language pathologists, and successfully piloted in a small case series of patients with voice problems. The investigators objective in this application is to test CTT in the rehabilitation of patients with voice disorders. The investigators hypothesize that, as demonstrated in the investigators preliminary case studies, these methods will result in early treatment success, and reduce the time required to reach therapeutic goals, thereby reducing costs associated with voice treatment.

Read the detailed description

Two common voice disorders, vocal fold lesions (lesions) and muscle tension dysphonia (MTD) constitute over 60% of voice clinic caseloads. Over 80% of patients with lesions and nearly 100% of those with MTD are treated exclusively with voice therapy.7,8 Traditional, bottom-up hierarchical, non-conversation based voice therapy is the established standard of care used most widely by speech-language pathologists (SLP) in clinical practice.e.g.3,9,10 However, the investigators group's published research indicated a clear need to target conversational voice use in treatment.2 Currently, no treatment program exists with a focus on voice use in conversation. Most voice therapy techniques are based in hierarchical, programmatic approaches aimed at manipulating phonatory physiology for voice improvement. These hierarchies necessitate that the final step in therapy is generalization of the target voice techniques to spontaneous, conversational speech.3 Three major problems exist with this approach to voice therapy, which the current proposal aims to address.

First, A hierarchical non-conversational approach to therapy builds treatment from unvoiced breathing to single sounds and rote phrases to connected speech to spontaneous every day conversation last, if at all, and patients are often discharged from therapy unable to generalize therapy techniques to conversation. Second, the use of a hierarchical, bottom-up approach necessitates a protracted time in treatment. Third, attrition rates for behavioral voice therapy are estimated between 16-65%,4,17 and voice problem relapse rates are between 51-68%.

02

Conditions studied

  • Voice Disorders

Browse trials for

Keywords

  • Voice Therapy
  • Muscle Tension Dysphonia
  • Lesions
03

In context

Voice Disorders

73 studies on the registry are indexed under Voice Disorders; 17 are open to participants now.

This study's enrollment of 67 is below the median of 100 across 25 observational studies indexed under Voice Disorders.

Browse Voice Disorders studies →

Lead sponsor

University of Pittsburgh is the lead sponsor of 1,385 studies on the registry; 167 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 4 (50%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Individuals diagnosed with either muscle tension dysphonia (MTD) or vocal fold lesion who are candidates for voice therapy.

Inclusion criteria

  • males and females
  • age 18-60 years old
  • diagnosed by a multi-disciplinary team consisting of laryngologist and speech-language pathologist with muscle tension dysphonia (MTD) or vocal fold lesions deemed amenable to voice therapy (i.e. not surgical candidates) using a standardized stimulability test developed by the research team (in revision for publication)

Exclusion criteria

Exclusion Criteria:

  • age 61 or greater
  • under 18 years of age
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
67 participants (actual)
Patient registry
No

Groups and cohorts

  • CTT group

    CTT will be initiated in a prospective fashion to study population

    Behavioral: Conversation Training Therapy

Interventions

  • BehavioralConversation Training Therapy

    Conversational speech as the primary focus of voice therapy in individuals with muscle tension dysphonia or vocal fold lesions.

06

What researchers measure

Primary outcomes

  1. Change in the Voice Handicap Index-10 (VHI-10)

    Time frame: Baseline through completion of therapy; approximately 6-8 months

07

Study locations

1 site
  • UPMC
    Pittsburgh, Pennsylvania 15213, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 8, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02441348
Lead sponsor
University of Pittsburgh
Responsible party
Jacqueline Gartner-Schmidt (Professor, University of Pittsburgh) — Principal investigator
First posted
May 12, 2015
Start date
May 11, 2016
Primary completion
Sep 2018
Completion
Sep 27, 2018
Last update
Jan 8, 2019

Study contacts

Amanda I Gillespie, PhD
principal investigator · University of Pittsburgh

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion